^
    Back
    Association details:
    Biomarker:HR positive
    Cancer:HER2 Positive Breast Cancer
    Drug:atirmociclib (PF-07220060) (CDK4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

    Excerpt:
    ...- Refractory Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) BC...
    Trial ID:
    NCT04557449
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+ HER2- mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy.

    Published date:
    05/25/2023
    Excerpt:
    PF-07220060 + ET showed efficacy in pts with HR+/HER2- mBC who progressed on prior CDK4/6i+ET. Tolerability of PF-07220060 alone and in combination with ET was encouraging. Dose expansions with PF-07220060 + ET in pts with HR+/HER2- mBC post CDK4/6i and in CDK4/6i naïve pts are ongoing.
    DOI:
    10.1200/JCO.2023.41.16_suppl.3009
    Trial ID:
    NCT04557449